Recruiting
Phase 2

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT04792073

Conditions

Merkel Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avelumab

Comprehensive Ablative Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information